Entasis Therapeutics, Inc.

Satenig Guler

Thomas Francois Durand-Reville

Janelle Comita-Prevoir

Neil Bifulco

Bolin Geng

Hoan Huynh

Brendan Chen

Shanta Bist

Hui Xiong

Liang Zhao

Daemian Dussault

Ye Wu

Ruben Alberto Tommasi

Xiaoyun Wu

Jing Zhang

Jan Romero

Helen McGuire

Mark Sylvester

Helen Mcguire

Camilo Velez-Vega

Helen Maureen Mcguire

Daemian David Dussault

Thomas Durand-Reville

Ruben Tommasi

Provided herein are antibacterial compounds represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, Y, R, R, and Rare as defined herein. Also provided are pharmaceutical compositions comprising the compounds of Formula I. 

Compounds and methods for treating bacterial infections

The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R, R, Rand Rare described herein.

&#x3b2;-lactamase inhibitor compounds

Beta-lactamase inhibitor compounds

Growing community of inventors

Waltham, MA, United States of America

Satenig Guler